×
Catalent Inventory 2012-2024 | CTLT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Catalent inventory for the quarter ending September 30, 2024 was
$0.553B
, a
30.53% decline
year-over-year.
Catalent inventory for 2024 was
$0.574B
, a
26.13% decline
from 2023.
Catalent inventory for 2023 was
$0.777B
, a
10.68% increase
from 2022.
Catalent inventory for 2022 was
$0.702B
, a
24.69% increase
from 2021.
View More
Catalent Inventory 2012-2024 | CTLT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Catalent inventory for 2024 was
$0.574B
, a
26.13% decline
from 2023.
Catalent inventory for 2023 was
$0.777B
, a
10.68% increase
from 2022.
Catalent inventory for 2022 was
$0.702B
, a
24.69% increase
from 2021.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$79.2B
Takeda Pharmaceutical (TAK)
$43.3B
Sandoz Group AG (SDZNY)
$19.5B
Merck (MKKGY)
$19.2B
Astellas Pharma (ALPMY)
$18.2B
United Therapeutics (UTHR)
$16.1B
Summit Therapeutics (SMMT)
$14.7B
Neurocrine Biosciences (NBIX)
$12.1B
Shionogi (SGIOY)
$11.9B
Jazz Pharmaceuticals (JAZZ)
$7.1B
Madrigal Pharmaceuticals (MDGL)
$6.9B
Orion OYJ (ORINY)
$6.7B
Corcept Therapeutics (CORT)
$5.7B
Ionis Pharmaceuticals (IONS)
$5.3B
Crinetics Pharmaceuticals (CRNX)
$5.1B
PTC Therapeutics (PTCT)
$3B
Dyne Therapeutics (DYN)
$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
Arrowhead Pharmaceuticals (ARWR)
$2.3B
Soleno Therapeutics (SLNO)
$2.2B
NewAmsterdam Pharma (NAMS)
$2.2B
Centessa Pharmaceuticals (CNTA)
$1.9B
Evotec AG (EVO)
$1.8B
Recursion Pharmaceuticals (RXRX)
$1.8B
Xencor (XNCR)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.5B
Indivior (INDV)
$1.4B
Harrow (HROW)
$1.4B
Ocular Therapeutix (OCUL)
$1.4B